Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Pacira Pharm Inc (PCRX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,191,250
  • Shares Outstanding, K 37,280
  • Annual Sales, $ 249,000 K
  • Annual Income, $ 1,860 K
  • 36-Month Beta 2.32
  • Price/Sales 4.59
  • Price/Book 5.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.95 +1.00%
on 12/02/16
38.20 -20.81%
on 11/15/16
-3.10 (-9.30%)
since 11/02/16
3-Month
29.95 +1.00%
on 12/02/16
43.31 -30.15%
on 09/19/16
-8.79 (-22.52%)
since 09/02/16
52-Week
29.95 +1.00%
on 12/02/16
80.25 -62.31%
on 12/29/15
-32.94 (-52.13%)
since 12/02/15

Most Recent Stories

More News
Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a patient-specific...

American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives

The American College of Surgeons (ACS) today announced a new multifaceted initiative to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives....

Research Reports Initiation on Healthcare Stocks -- Perrigo, Pacira Pharma, Supernus Pharma, and PerkinElmer

This morning, Stock-Callers.com has lined up the following healthcare stocks for assessment following a positive Monday's session where gains were broad based as all nine sectors ended the session in green:...

Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL(R) in Total Knee Replacement Surgery

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today introduced a revolutionary new virtual reality simulation intended to provide clinicians with an immersive, hands-on training experience to reinforce the...

Pacira (PCRX) Misses Q3 Earnings Estimates, Beats on Sales

Pacira Pharmaceuticals, Inc. (PCRX) reported third-quarter 2016 earnings of 2 cents (including the impact of stock-based compensation).

Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results

-- Total Net Revenues Up 10% Year-Over-Year --

What Falling Estimates & Price Mean for Pacira Pharmaceuticals (PCRX)

Pacira Pharmaceuticals (PCRX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks

Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of two key individuals who will assume leadership roles within the company's commercial organization. Thomas Sluby has been named...

Pacira Pharmaceuticals Announces Timing for Third Quarter 2016 Financial Results Webcast and Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company's third quarter ended September 30, 2016 will be released before the market opens on Wednesday, November...

Healthcare Sector Earnings Review for Healthways, Amphastar Pharma, Pacira Pharma, and Insys Therapeutics

LONDON, UK / ACCESSWIRE / September 26, 2016 / Active Wall St. announces its coverage of top earnings surprises within the Healthcare Sector. As on September 16, 2016, 499 companies within the S&P 500...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Support & Resistance

2nd Resistance Point 31.98
1st Resistance Point 31.12
Last Price 30.25
1st Support Level 29.67
2nd Support Level 29.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.